湖南达嘉维康医药产业股份有限公司 2022 年第三季度报告 证券代码：301126 证券简称：达嘉维康 公告编号：2022-055 湖南达嘉维康医药产业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 湖南达嘉维康医药产业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 844,361,824.95 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2022-054 湖南达嘉维康医药产业股份有限公司 关于参加湖南辖区上市公司 2022 年 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为贯彻落实《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护 工作的意见》文件精神，进一步加强与广大投资者的沟通交流，使投资者能更加深 入的了解公司的经营及未来的发展情况，湖南达嘉维康医药产业股份有限公司（以 下简称"公司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司协 会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司2022年投资者网上集 体接待日活动"，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互联网 平台，采取网络远程的方式进行，投资者可以登录"全景路演"网站（http://rs.p5w.net） 参与公司本次投资者网上接待日活动，活动时间为2022年9月29日（星期四）15:30- 16:55。 届时公司董事会秘书柴丹妮女士、证券事务代表蒋茜女士将通过网络在线 ...

Financial Performance - The company reported a revenue of 1.5 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders for the same period was 200 million RMB, up 10% compared to the previous year[15]. - The company's operating revenue for the reporting period was ¥1,395,467,591.78, representing an increase of 11.24% compared to the same period last year[22]. - The net profit attributable to shareholders was ¥38,210,825.98, an increase of 8.75% year-on-year[22]. - The company's total operating revenue for the first half of 2022 reached ¥1,395,467,591.78, an increase of 11.26% compared to ¥1,254,499,674.84 in the same period of 2021[146]. - Net profit for the first half of 2022 was ¥38,210,825.98, representing a 8.00% increase from ¥35,137,758.83 in the first half of 2021[148]. Market Expansion and Strategy - User data indicates a growth in active customers by 20%, reaching 1 million users by the end of June 2022[15]. - The company plans to expand its market presence by opening 50 new retail locations in the next year[15]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[15]. - The company aims to strengthen its market position by increasing the proportion of non-bid distribution business and expanding its service offerings[35]. - The company is actively expanding its chain pharmacy business by acquiring chain pharmacies in key provinces, aiming to increase its chain rate in the second half of the year[76]. Research and Development - Research and development expenses increased by 25%, totaling 100 million RMB, focusing on new drug formulations and technologies[15]. - The company aims to enhance its market presence and product offerings through strategic investments and potential acquisitions in the healthcare sector[148]. - Future outlook includes continued focus on innovation and expansion in the pharmaceutical industry to drive growth and profitability[148]. Financial Position and Cash Flow - The net cash flow from operating activities was -¥250,539,518.07, a significant decline of 462.83% compared to the previous year[22]. - Total assets at the end of the reporting period reached ¥3,167,509,924.11, up 5.78% from the end of the previous year[22]. - The net assets attributable to shareholders increased to ¥1,710,334,011.63, reflecting a growth of 1.86% year-on-year[22]. - The company's short-term borrowings increased to ¥767,432,741.66, up 4.55% from ¥589,251,169.85 at the end of the previous year[50]. - The company reported a net increase in cash and cash equivalents of -¥263,735,860.66, a decline of 888.41% compared to an increase of ¥33,451,649.62 in the previous year[43]. Risks and Challenges - The management highlighted risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[3]. - The company faces risks related to national medical insurance negotiations and price reductions that could affect revenue, necessitating strategic adjustments[73]. - The implementation of a "one invoice system" could significantly reduce the revenue scale of the company's distribution business if not timely adjusted to policy changes[74]. Corporate Governance and Shareholder Information - The company has not reported any significant changes in its profit structure or sources during the reporting period[44]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[65][66][67]. - The company has not sold any significant assets during the reporting period[68]. - The company has not reported any changes in the shareholding of directors, supervisors, and senior management during the reporting period[127]. - The company’s shareholders include significant holdings by various entities, with the largest shareholder holding 70,144,219 shares[122]. Social Responsibility and Community Engagement - The company donated 2,700 bottles of 75% alcohol (500ml) and 30,000 medical masks to support COVID-19 prevention efforts in Huaihua[88]. - The company has committed to social responsibility initiatives, including donations to support rural health and disaster relief efforts[89]. Accounting and Financial Reporting - The company's financial report for the half-year period was not audited[136]. - The company adheres to the accounting standards for enterprises, ensuring that the financial statements reflect a true and complete picture of its financial status and operating results[185]. - The company utilizes the Chinese Yuan (RMB) as its functional currency for accounting purposes[188].

湖南达嘉维康医药产业股份有限公司 2022 年第一季度报告全文 证券代码：301126 证券简称：达嘉维康 公告编号：2022-021 湖南达嘉维康医药产业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 单位：元 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 627,481,511.98 | 577,067,972.14 | 8.74% | | 归属于上市公司股东的净利润（元） | 19,024,073.2 ...

Financial Performance - The company reported a cash dividend of 0.34 RMB per 10 shares for a total of 206,505,700 shares, amounting to approximately 70.2 million RMB[7]. - The company’s financial statements were confirmed to be accurate and complete by its management, ensuring transparency for investors[6]. - The company’s annual report includes a comprehensive analysis of its financial performance and strategic direction for the upcoming year[9]. - The company's operating revenue for 2021 was CNY 2,592,177,298.59, representing a 10.79% increase compared to CNY 2,339,769,111.79 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 68,258,852.74, a 5.25% increase from CNY 64,853,965.17 in 2020[23]. - The total assets at the end of 2021 amounted to CNY 2,994,307,163.51, a significant increase of 37.83% from CNY 2,172,529,726.34 at the end of 2020[23]. - The net assets attributable to shareholders increased by 61.13% to CNY 1,679,144,379.44 at the end of 2021, up from CNY 1,042,098,322.71 at the end of 2020[23]. - The basic earnings per share for 2021 was CNY 0.44, reflecting a 4.76% increase from CNY 0.42 in 2020[23]. - The company achieved a net profit of RMB 68,258,852.74 for the year 2021, with a mother company net profit of RMB 1,657,799.64[162]. - Total revenue for 2021 reached ¥2,592,177,298.59, representing a year-on-year increase of 10.79% compared to ¥2,339,769,111.79 in 2020[56]. Market Expansion and Strategy - The report indicates that the company is focused on expanding its market presence and enhancing its product offerings through new technologies and research initiatives[7]. - The company is transitioning from traditional pharmaceutical distribution to a comprehensive smart healthcare service provider, focusing on chronic disease management and clinical service solutions[39]. - The company is actively participating in the new round of mergers and acquisitions in the pharmaceutical distribution industry to enhance market influence and coverage[34]. - The company is expanding its e-commerce business by leveraging AI and big data for precise marketing, aiming to integrate online and offline sales channels[98]. - The company plans to focus on hospital distribution as a performance foundation and expand through chain pharmacies, leveraging the "Internet + drug distribution" model[96]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[135]. - The company is expanding its market presence, targeting an increase in distribution channels by 25% in the next year to enhance accessibility[181]. - The company plans to launch three new products in 2022, focusing on innovative drug formulations and advanced delivery systems[135]. Governance and Compliance - The company’s governance structure includes a board of directors and supervisory board, ensuring accountability and oversight in its operations[6]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[115]. - The supervisory board is composed of 6 members, with effective oversight on financial and major operational decisions, ensuring compliance with relevant laws[116]. - The company has confirmed that there are no related party transactions that could significantly impact its independence or fairness[124]. - The company has not faced any penalties from securities regulatory authorities in the past three years[140]. - The company has a clear and transparent decision-making process for profit distribution, ensuring the protection of minority shareholders' rights[159]. - The company has established a commitment to ensure the stability of its operations post-IPO[178]. Risk Management - The company emphasized the importance of risk awareness regarding future plans and projections, highlighting potential risks and countermeasures in its management discussion[7]. - The company faces risks from national healthcare negotiations and price reductions that could impact revenue, particularly in the context of ongoing healthcare reforms[100]. - The company has not identified any risks during the supervisory activities of the supervisory board in the reporting period[151]. Research and Development - The company has a strong commitment to research and development, aiming to innovate and improve its product offerings[130]. - Investment in R&D increased by 30% in 2021, with a focus on developing new technologies in the pharmaceutical sector[135]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[200]. Employee and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.5585 million[142]. - The company has a structured employee compensation system based on ability and contribution, with salaries adjusted annually according to market conditions and individual performance[155]. - The total number of employees at the end of the reporting period is 1,240, with 629 in the parent company and 611 in major subsidiaries[152]. Community Engagement and Social Responsibility - The company donated 200,000 yuan to improve the "medicinal and fruit intercropping" industry project in a poverty alleviation initiative[174]. - The company contributed 50,000 yuan to support rural education and 273,343 yuan through a teacher training fund[174]. - The company has actively participated in poverty alleviation efforts since 2017, focusing on infrastructure and agricultural development in partnership with local communities[173]. Future Outlook - Future performance guidance indicates a positive outlook, with expectations for revenue growth in the upcoming fiscal year[130]. - The company provided a positive outlook for 2022, projecting a revenue growth of 10% to 12% based on market expansion strategies and new product launches[191]. - The company aims to enhance shareholder value through transparent communication and adherence to regulatory requirements regarding related party transactions[181].